Korean Journal of Biological Psychiatry (생물정신의학)

The Korean Society of Biological Psychiatry (대한생물정신의학회)
권호 표지

Association Study between Treatment Response of Amisulpride and Dopamine D3 Receptor Gene Polymorphisms

조현병 환자에서 아미설프라이드의 치료반응과 도파민 D3 수용체 유전자다형성의 연관성

  • Kang, Seung-Gul (Department of Psychiatry, Gil Medical Center, Gachon University School of Medicine) ;
  • Lee, Heon-Jeong (Department of Psychiatry, Korea University College of Medicine) ;
  • Lee, Seung Jae (Department of Psychiatry, Kyungpook National University School of Medicine) ;
  • Choi, Tae Young (Department of Psychiatry, Catholic University of Daegu School of Medicine) ;
  • Woo, Jungmin (Department of Psychiatry, Catholic University of Daegu School of Medicine) ;
  • Kim, Jihyun (Department of Psychiatry, Catholic University of Daegu School of Medicine) ;
  • Jung, Sung-Won (Department of Psychiatry, Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Koo, Bon Hoon (Department of Psychiatry, College of Medicine, Yeungnam University) ;
  • Lee, Kwanghun (Department of Psychiatry, Dongguk University College of Medicine) ;
  • Kim, Jeong-Lan (Department of Psychiatry, School of Medicine, Chungnam National University) ;
  • Chee, Ik-Seung (Department of Psychiatry, School of Medicine, Chungnam National University) ;
  • Lee, Jonghun (Department of Psychiatry, Catholic University of Daegu School of Medicine)
  • 강승걸 (가천대학교 의학전문대학원 길병원 정신건강의학교실) ;
  • 이헌정 (고려대학교 의과대학 정신건강의학교실) ;
  • 이승재 (경북대학교 의학전문대학원 정신건강의학교실) ;
  • 최태영 (대구가톨릭대학교 의과대학 정신건강의학교실) ;
  • 우정민 (대구가톨릭대학교 의과대학 정신건강의학교실) ;
  • 김지현 (대구가톨릭대학교 의과대학 정신건강의학교실) ;
  • 정성원 (계명대학교 의과대학 정신건강의학과교실) ;
  • 구본훈 (영남대학교 의과대학 정신건강의학교실) ;
  • 이광헌 (동국대학교 의과대학 경주병원 정신건강의학교실) ;
  • 김정란 (충남대학교 의학전문대학원 정신건강의학교실) ;
  • 지익성 (충남대학교 의학전문대학원 정신건강의학교실) ;
  • 이종훈 (대구가톨릭대학교 의과대학 정신건강의학교실)
  • Received : 2013.05.27
  • Accepted : 2013.06.19
  • Published : 2013.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives The aim of this study is to evaluate the association between rs6280 and rs905568 genetic polymorphism of DRD3 gene and the treatment response of amisulpride. Methods After six weeks treatment of amisulpride, 125 schizophrenia patients were interviewed based on the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression-Severity (CGI-S). The genotyping for rs6280 and rs905568 was performed using TaqMan single nucleotide polymorphism (SNP) genotyping assay. Results There was no significant difference in the frequency of genotype and allele of rs6280 between the responders and non-responders based on the total, positive, and general score of PANSS and CGI-S score. However, there was a significant association between this SNP and treatment response in the negative score of PANSS (${\chi}^2=5.23$, p = 0.022). There was no significant association between rs905568 and the response in positive, negative, general, and total PANSS score and CGI-S score. Conclusions This is the first positive association study between DRD3 gene and the treatment response of negative symptoms to amisulpride in Korean schizophrenia patients. A larger scale research on more SNP of the DRD3 gene will make a progress in the study of pharmacogenetics on the treatment response of the amisulpride.

Keywords

References

  1. Moller HJ, Boyer P, Fleurot O, Rein W. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. Psychopharmacology (Berl) 1997; 132:396-401. https://doi.org/10.1007/s002130050361
  2. Puech A, Fleurot O, Rein W. Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr Scand 1998;98:65-72. https://doi.org/10.1111/j.1600-0447.1998.tb10044.x
  3. Mortimer A, Martin S, LÔo H, Peuskens J; SOLIANOL Sudy Group. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol 2004;19:63-69. https://doi.org/10.1097/00004850-200403000-00002
  4. Peuskens J, Bech P, MÖller HJ, Bale R, Fleurot O, Rein W. Amisul- pride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res 1999;88:107- 117. https://doi.org/10.1016/S0165-1781(99)00075-X
  5. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085-1097. https://doi.org/10.1016/S0140-6736(08)60486-9
  6. Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002;159:180-190. https://doi.org/10.1176/appi.ajp.159.2.180
  7. Colonna L, Saleem P, Dondey-Nouvel L, Rein W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol 2000;15:13-22. https://doi.org/10.1097/00004850-200015010-00002
  8. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990;347:146-151. https://doi.org/10.1038/347146a0
  9. Sokoloff P, Martres MP, Giros B, Bouthenet ML, Schwartz JC. The third dopamine receptor (D3) as a novel target for antipsychotics. Biochem Pharmacol 1992;43:659-666. https://doi.org/10.1016/0006-2952(92)90227-A
  10. Jeanneteau F, Funalot B, Jankovic J, Deng H, Lagarde JP, Lucotte G, et al. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A 2006;103:10753-10758. https://doi.org/10.1073/pnas.0508189103
  11. Jonsson EG, Flyckt L, Burgert E, Crocq MA, Forslund K, Mattila-Evenden M, et al. Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis. Psychiatr Genet 2003;13:1-12. https://doi.org/10.1097/00041444-200303000-00001
  12. Hwang R, Zai C, Tiwari A, Muller DJ, Arranz MJ, Morris AG, et al. Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J 2010;10: 200-218. https://doi.org/10.1038/tpj.2009.65
  13. Zai CC, Tiwari AK, De Luca V, Müller DJ, Bulgin N, Hwang R, et al. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. Eur Neuropsychopharmacol 2009;19:317-328. https://doi.org/10.1016/j.euroneuro.2009.01.001
  14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text-Revision. Washington DC: American Psychiatric Publishing, Inc.;2000.
  15. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
  16. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276. https://doi.org/10.1093/schbul/13.2.261
  17. Joyce JN, Millan MJ. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today 2005;10:917-925. https://doi.org/10.1016/S1359-6446(05)03491-4
  18. Lane HY, Hsu SK, Liu YC, Chang YC, Huang CH, Chang WH. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J Clin Psychopharmacol 2005;25:6-11. https://doi.org/10.1097/01.jcp.0000150226.84371.76
  19. Lundstrom K, Turpin MP. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 1996;225:1068-1072. https://doi.org/10.1006/bbrc.1996.1296
  20. Shaikh S, Collier DA, Sham PC, Ball D, Aitchison K, Vallada H, et al. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum Genet 1996;97:714- 719. https://doi.org/10.1007/BF02346178
  21. Xuan J, Zhao X, He G, Yu L, Wang L, Tang W, et al. Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study. Neuropsychopharmacology 2008; 33:305-311. https://doi.org/10.1038/sj.npp.1301418
  22. Kim B, Choi EY, Kim CY, Song K, Joo YH. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Hum Psychopharmacol 2008; 23:61-67. https://doi.org/10.1002/hup.897
  23. Chen SF, Shen YC, Chen CH. Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:470-474. https://doi.org/10.1016/j.pnpbp.2009.01.007
  24. Kim HC, Jung SW, Kim DK. The relationship between the antipsychotics- induced weight gain and the dopamine D2, D3, and D4 receptor gene polymorphisms in Korean. Korean J Psychopharmacol 2007;18:299-307.